LONDON, Oct. 19, 2016 /PRNewswire/ -- This report
provides a comprehensive overview of the size of cancer
immunotherapy market, the segmentation of the market, key players
and the vast potential of therapies that are in clinical trials.
Oncologic therapeutics cannot cure cancer and yet in 2014, the
overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a
reasonable survival of more than five years for cancer patients can
achieve a blockbuster status. Within cancer therapeutics,
immunotherapeutic drugs have gained worldwide acceptance, because
they are targeted drugs targeting only cancer cells. Today, cancer
immunotherapy drugs have captured nearly 50% of the overall
oncology drugs market, generating about $41.0 billion in 2014 alone. This report
describes the evolution of such a huge market in 20 chapters
supported by over 180 tables and figures in 317 pages.
-An overview of cancer immunotherapy that includes: monoclonal
antibodies, cancer vaccines and non-specific cancer immunotherapies
and CAR T therapies.
-Focus on current trends in cancer immunotherapies that include:
anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and
cancer vaccines.
-Insight into the challenges faced by drug developers, particularly
about the success vs. failure ratios in developing cancer
immunotherapy drugs.
-Descriptions of more than 23 cancer immunotherapeutics approved
and used as targeted drugs
-Insight into the various immunotherapeutics available for specific
cancer types.
-Description and data for the prevalence of cancer types that are
addressed by cancer immunotherapeutics.
-Overall global cancer therapeutics market, leading market players
and the best selling cancer drugs.
-Detailed account of the market for cancer immunotherapeutics by
geography, indication, company and individual drugs.
-Profiles, marketed products and products in the pipeline of 79
companies that are mostly located in the U.S. and Europe.
-Summary table to identify the category of immunotherapy drug
offered by the 79 companies.
1.2 Key Questions Answered in this Report
-What is the global market for cancer immunotherapeutics by product
class such as MAbs, vaccines and non-specific immunotherapies,
through 2020?
-What is the global market for cancer immunotherapeutics by
geography, through 2020?
-What is the global market for cancer immunotherapeutics by
indication, through 2020?
-What is the global market for MAbs by type such as naked MAbs and
ADCs, through 2020?
-What are the market values for Herceptin, Avastin, Erbitux,
Yervoy, Mabthera, Adectris, and Keytruda?
-What is the global market for cancer vaccines?
-What is the global market for cytokines in cancer
immunotherapy?
-The projected market values for Nivolumab, RG7446, DCVax-L,
MEDI4736 etc.?
-What immunotherapies were approved between 1986 and 2016?
-What monoclonal antibodies (MAbs) were approved by the FDA to
treat different types of cancers?
-What are naked MAbs and how many of them have been approved by the
FDA?
-What are antibody-drug conjugates (ADCs) and how many of them are
available in the market?
-What are the common cytotoxic "wareheads" used in ADCs?
-What are the important clinical assets in ADCs?
-How many bispecific MAbs are in late-stage development?
-What are the common side effects of MAbs in cancer
immunotherapy?
-What are cancer vaccines and how many of them have been licensed
to be marketed?
-How many cytokines have been approved for being used in cancer
immunotherapy?
-What are the major checkpoint inhibitors in clinical
development?
-What is the current status of anti-PD-1 drugs, dentritic cell
therapies, T-cell therapies and cancer vaccines?
-What are the most valuable R&D projects in cancer
immunotherapy and what would be their approximate sales revenues in
2020 Number of melanoma drugs approved between 1998 and 2016?
-Number of lung cancer drugs approved between 1998 and 2016?
-Number of brain cancer drugs approved between 1998 and 2016?
-What is CAR T Therapy?
-What are the main challenges associated with CAR T therapy?
-When will the first CAR T therapeutics be approved?
-What are the current regulations for immunotherapies in USA,
Europe & Japan?
-What are the main manufacturing steps in CAR T therapy?
-What challenges lie ahead for CAR T production?
Executive Summary
Prior to the launching of Yervoy, the five-year survival rate for
patients with early stage melanoma was 98%; but the five-year
survival rate for late-stage melanoma was just 16%. Yervoy has been
reported to have a survival rate of 25% when tested alone. When
tested as part of a combination therapy treatment with Bristol's nivolumab, the two-year survival
rates rose to 88% for patients with late-stage cancer. Increase in
patient survival rates brought about by cancer immunotherapy
treatment is similar to that seen when bone marrow transplantation
changed our conception on how blood cancer was treated.
Therefore, it is no wonder that in 2013, most science journals
hailed cancer immunotherapy as the breakthrough treatment of the
year. Conceivably, what makes advancements in cancer immunotherapy
research even more dramatic is the fact it has the potential to
treat a wide range of tumor types. If the present trends continue,
cancer immunotherapy drugs will have a market value of about
$80 billion in 2020. A single drug,
Bristol-Myers Squibb's Yervoy, for example has earned revenues of
about $960 million in 2013 and it is
expected to have a market value of $1,775.2
million in 2020.
Recently, a new class of anti-cancer agents called checkpoint
inhibitors has hit the market. In the first week of September 2014, Bristol-Myers Squibb and Ono
Pharmaceutical launched their PD-1 (programmed cell death-1)
inhibitor Opdivo (nivolumab) in Japan for unresectable melanoma. Later, Merck
got FDA clearance for PD-1 inhibitor Keytruda (pembrolizumab) for
unresectable melanoma following the treatment with Yervoy
(ipilimumab).
In the U.S., Opdivo was granted approval in 2015 for renal
carcinoma, non-small-cell lung cancer (NSCLC) and previously
treated advanced melanoma. In May
2016, Opdivo was granted FDA approval for the treatment of
patients with classical Hodgkin lymphoma (cHL) that has relapsed or
progressed after autologous hematopoietic stem cell transplantation
(HSCT).
Keytruda (pembrolizumab), another PD-1 inhibitor was granted FDA
approval in October 2015 for advanced
NSCLC, and was granted EMA approval for melanoma in July 2015. Both Keytruda and Opdivo have six
figure price tags in the market. Keytruda will cost $12,500 a month and Merck says the median usage
is 6.2 months, which works out to a $77,500 price tag, or $150,000 on annualized basis. In Japan, Opdivo costs about $143,000 a patient. Industry experts have
predicted that Keytruda and Opdivo will generate sales revenues of
$2.9 billion and $4.3 billion respectively in 2019.
Another area of anticancer therapy is cancer vaccines. There are
two different types of cancer vaccines: prophylactic vaccines to
prevent cancers from occurring, and therapeutic vaccines to treat
pre-existing cancers. A few prophylactic vaccines for
viral-associated cancers have had significant success, such as the
human papillomavirus vaccine that helps prevent cervical cancer. On
the other hand, therapeutic vaccines have proven much more elusive
and a string of failures bred significant skepticism. Ultimately,
in 2010, perseverance paid off and the first therapeutic vaccine
sipuleucel-T for the treatment of metastatic prostate cancer was
approved by the FDA: In spite of its financial restructuring
efforts, Dendreon earned $303.8
million in 2014 which was $20.1
million more than its 2013 sales revenue.
The CAR-T industry is addressing unmet needs in specific relapsed
cancers, however does early clinical trial data support a
blockbuster status for this upcoming therapy? Some patients do
indeed show long term activity and high remission rates, but there
is a large proportion of patients with toxicities such as cytokine
release syndrome and neurotoxicity. The main players within the
CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and
Cellectis. The market is moving ahead, backed by years of R&D,
from both academia and industry, investors capitol and small
clinical studies. From 2017, Kelly Scientific forecasts that CAR T
therapy will become more streamlined, with faster manufacturing
times as advances in technologies take hold and clinical trials
provide more robust evidence that this immunotherapy is robust.
These factors, plus strategies to reduce adverse reactions and
toxicities and larger players like Novartis taking stage will push
CAR T therapy ahead. However, recent deaths in the Juno ROCKET
trial are creating questions amongst investors. How will the CAR T
space influence the total immunotherapy industry going forward?
This comprehensive report scrutinizes the total market and provides
cutting-edge insights and analysis.
Download the full report:
https://www.reportbuyer.com/product/3994839/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global--usa-cancer-immunotherapy-market-analysis-to-2020-antibody-drug-conjugates--bispecific-monoclonal-antibodies-cancer-vaccines-cytokines-interferons-chimeric-antigen-receptor-t-cell-therapy-pd-1pd-l1-inhibitors-dend-300348077.html
SOURCE ReportBuyer